Your browser doesn't support javascript.
loading
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein, Harold J; Harris, Lyndsay N; Marcom, P Kelly; Lambert-Falls, Rosemary; Havlin, Kathleen; Overmoyer, Beth; Friedlander, Robert J; Gargiulo, Janet; Strenger, Rochelle; Vogel, Charles L; Ryan, Paula D; Ellis, Mathew J; Nunes, Raquel A; Bunnell, Craig A; Campos, Susana M; Hallor, Michele; Gelman, Rebecca; Winer, Eric P.
Afiliação
  • Burstein HJ; Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. hburstein@partners.org.
J Clin Oncol ; 21(15): 2889-95, 2003 Aug 01.
Article em En | MEDLINE | ID: mdl-12885806
Assuntos
Buscar no Google
Imprimir
XML
PubMed Links

Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vimblastina / Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2003 Tipo de documento: Article
Buscar no Google
Imprimir
XML
PubMed Links

Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vimblastina / Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Ano de publicação: 2003 Tipo de documento: Article